Impaired interleukin-12 production in multiple sclerosis patients

Abstract

Multiple sclerosis (MS), a disease of the human central nervous system, is believed to be a T cell mediated autoimmune disorder with genetic and environmental influences. Interleukin-12 (IL-12), a proinflammatory cytokine produced primarily by antigen presenting cells is a potent inducer of interferon-g (IFN-g) and other Th1 cytokines that may play an important role in MS pathogenesis. We have investigated IL-12 production induced by the T cell independent pathway in untreated and IFN-b treated MS patients, healthy individuals and other neurological disease (OND) patients in response to the human pathogen Staphylococcus aureus. We report that peripheral blood mononuclear cells (PBMC) from untreated MS patients produce normal amounts of the biologically active IL-12 p70 heterodimer but significantly less free IL-12 p40 heavy chain than PBMC from both healthy and disease controls when challenged in vitro with Staphylococcus aureus. Both mRNA expression of the inducible IL-12 p40 chain and protein levels were found to be reduced in untreated MS patients. No decrease in the production of the IL-12 p40 was seen in MS patients on IFN-b therapy. The decreased production of IL-12 p40 heavy chain is not attributed to increased IL-10 secretion, a defect in the production of cytokines by macrophages or the number of cytokine producing cells. The factor(s) responsible for the decrease in p40 remain to be determined. Since IL-12 p40 antagonizes the biological activity of IL-12 in vitro and in vivo, identification of a defect in the `natural' antagonist of IL-12, may provide the basis for immune therapy.

Keywords

multiple sclerosis interleukin-12 (p402) antagonist

Get full access to this article

View all access options for this article.

References

Kobayashi M et al. (1989) Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes . J Exp Med 170: 827-845 .

Stern AS et al. (1990) Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human b-lymphoblastoid cells . Proc Natl Acad Sci USA 87: 6808-6812 .

D'Andrea A et al. (1992) Production of natural killer cell stimulatory factor (interleukin-12) by peripheral blood mononuclear cells . J Exp Med 176: 1387-1398 .

Trinchieri G. (1994) Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes . Blood 84: 4008-4027 .

Maruo S et al. (1996) IL-12 produced by antigen-presenting cells induces IL-2-independent proliferation of T helper cell clones . J Immunol 156: 1748-1755 .

Shu U et al. (1995) Activated T cells induce interleukin- 12 production by monocytes via CD40-CD40 ligand interaction . Eur J Immunol 25: 1125-1128 .

Gately MK , Wolitzky AG , Quinn PM , Chizzonite R. (1992) Regulation of human cytolytic lymphocyte responses by interleukin-12 . Cell Immunol 143: 127-142 .

de Waal Malefyt R et al. (1991) Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes . J Exp Med 174: 1209-1220 .

D'Andrea A et al. (1993) Interleukin 10 (IL-10) inhibits human lymphocyte interferon-g production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells . J Exp Med 178: 1041-1048 .

10.

Ling P et al. (1995) Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity . J Immunol 154: 116-127 .

11.

Gillessen S et al. (1995) Mouse interleukin-12 (IL-12) p40 homodimer: a potent IL-12 antagonist . Eur J Immunol 25: 200-206 .

12.

Kato K et al. (1996) Local production of the p40 subunit of interleukin 12 suppresses T-helper 1-mediated immune responses and prevents allogeneic myoblast rejection . Proc Natl Acad Sci USA 93: 9085-9089 .

13.

Panitch HS , Hirsch RL , Haley AS , Johnson KP. (1987) Exacerbations of multiple sclerosis in patients treated with gamma interferon . Lancet. i: 893-895 .

14.

Beck J et al. (1988) Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: Do cytokines trigger off exacerbations? Acta Neurol Scand 78: 318-323 .

15.

Lu C-Z , Jensen MA , Arnason GW. (1993) Interferon g-and interleukin-4 - secreting cells in multiple sclerosis . J Neuroimmunol 46: 123-128 .

16.

Woodroofe MN , Cuzner ML. (1993) Cytokine mRNA expression in inflammatory multiple sclerosis lesions: detection by non-radioactive in situ hybridization . Cytokine 5: 583-588 .

17.

Balashov KE et al. (1997) Increased interleukin 12 production in progressive multiple sclerosis: Induction by activated CD4+ T cells via CD40 ligand . Proc Natl Acad Sci USA 94: 599-603 .

18.

Leonard JP , Waldburger KE , Goldman SJ. (1995) Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12 . J Exp Med 181: 381-386 .

19.

Issazadeh S et al. (1995) Cytokine production in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis: dynamics of mRNA expression for interleukin-10, interleukin-12, cytolysin, tumor necrosis factor-a and tumor necrosis factor-b . J Neuroimmunol 61: 205-212 .

20.

Poser CM et al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols . Ann Neurol 13: 227-231 .

21.

Chomczymski P , Sacchi N. (1987) Single step method of RNA isolation by acid guanidinium thiocyinate-phenol-chloroform extraction . Anal Biochem 162: 156-159 .

22.

Ma X et al. (1996) The interleukin 12 p40 gene promoter is primed by interferon g in monocytic cells . J Exp Med 183: 147-157 .

23.

Krämer B , Wiegmamn K , Krönke M. (1995) Regulation of the human TNF promoter by the transcription factor ets . J Biol Chem 270: 6577-6583 .

24.

Murphy TL et al. (1995) Regulation of interleukin 12 p40 expression through an NF-kB half-site . Mol Cell Biol 15: 5258-5267 .

25.

Noronha A , Toscas A , Jensen MA. (1993) Interferon b decreases T cell activation and interferon g production in multiple sclerosis . J Neuroimmunol 46: 145-154 .

26.

Rudick RA et al. (1996) Interferon beta induces inter-leukin-10 expression: relevance to multiple sclerosis . Ann Neurol 40: 618-627 .

27.

Rep MHG , Hintzen RQ , Polman CH , vanLier RAW. (1996) Recombinant interferon-b blocks proliferation but enhances interleukin-10 secretion by activated human T-cells . J Neuroimmunol 67: 111-118 .

28.

Ferrante P et al. (1998) Cytokine production and surface marker expression in acute and stable multiple sclerosis: Altered IL-12 production and augmented signaling lymphocytic activation molecule (SLAM)-expressing lymphocytes in acute multiple sclerosis . J Immunol 160: 1514-1521 .

29.

Panitch HS. (1994) Influence of infection on exacerbations of multiple sclerosis . Ann Neurol 36 (Suppl): S25-S28 .

30.

Segal BM , Klinman DM , Shevach EM. (1997) Microbial products induce autoimmune disease by an IL-12- dependent pathway . J Immunol 158: 5087-5090 .

31.

Wucherpfennig KW , Strominger JL. (1995) Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein . Cell 80: 695-705 .

32.

Seder RA , Kelsall BL , Jankovic D. (1996) Differential roles for IL-12 in the maintenance of immune responses in infectious versus autoimmune disease . J Immunol 157: 2745-2748 .

33.

Lad N. (1997) Interleukin-12: A new target for immunosuppressive therapy in multiple sclerosis . IBC 5th Annual Conference on Multiple Sclerosis, Cambridge, MA.